Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics’ fiscal second quarter of 2026 beat EPS expectations while revenue missed consensus, with results reported Aug. 6 as revenue fell about 88% year over year to roughly $3.0 million. Revenue of about $3.0 million missed the $3.1 million consensus by about 5%, while gross profit also came in at about $3.0 million, leaving gross margin near 100% and operating margin around -863% as the company posted an operating loss of roughly $25.5 million. Net income fell about 159% to a loss of roughly $23.8 million from $9.2 million a year ago, and EPS of -$0.84 beat the -$1.00 estimate by about 16% even as it was down about 147% from -$0.34 a year ago. Operating cash flow was negative $39.4 million. Consensus for the next period calls for EPS of -$0.92 on revenue of $4.1 million.